Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

被引：0

作者：

Haricharan, Svasti ^{[1
]}

Punturi, Nindo ^{[1
]}

Seker, Sinem ^{[1
]}

Devarakonda, Vaishnavi ^{[2
]}

Kalra, Rashi ^{[2
]}

Chen, Ching-Hui ^{[2
]}

Mazumder, Aloran ^{[1
]}

Li, Shungqiang ^{[3
]}

Primeau, Tina ^{[3
]}

Ellis, Matthew ^{[2
]}

Kavuri, Shyam ^{[2
]}

机构：

[1] Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA USA

[2] Baylor Coll Med, Houston, TX 77030 USA

[3] Washington Univ, St Louis, MO 63110 USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PD8-05

引用

页数：1

共 50 条

[31] Can HER2 1+Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
Shu, Lan
Tong, Yiwei
Li, Zhuoxuan
Chen, Xiaosong
Shen, Kunwei
CANCERS, 2022, 14 (17)
[32] Her2 FISH amplification in ER/PR/Her2 IHC negative breast cancer
Sahoo, Sunati
Hwang, Helena
CANCER RESEARCH, 2015, 75
[33] Exploration of HER2 gene tyrosine kinase domain in HER2-negative breast cancer in saudi patients: preliminary study
Albogomi, Sarah
Mani, Rahma
Alattas, Afnan
Monstaser, Metwally Mohamed
Sadik, Atef
Abdelaziz, Amany Mamdouh
Elkholy, Engi Mouawad
Nemenqani, Dalai Mohideen
Mabrouk, Imed
BIOSCIENCE RESEARCH, 2018, 15 (04): : 3850 - 3859
[34] HER2 Pro1170Ala polymorphism is associated with decreased survival rate in HER2-negative breast cancer
Si, Pilei
Xu, Ye
Ouyang, Tao
Li, Jinfeng
Wang, Tianfeng
Fan, Zhaoqing
Fan, Tie
Lin, Benyao
Xie, Yuntao
ONCOLOGY LETTERS, 2017, 13 (05) : 3793 - 3798
[35] Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer
Bidard, F. -C.
Ng, C. K. Y.
Cottu, P.
Piscuoglio, S.
Escalup, L.
Sakr, R. A.
Reyal, F.
Mariani, P.
Lim, R.
Wang, L.
Norton, L.
Servois, V.
Sigal, B.
Vincent-Salomon, A.
Weigelt, B.
Pierga, J. -Y.
Reis-Filho, J. S.
ANNALS OF ONCOLOGY, 2015, 26 (08) : 1704 - 1709
[36] HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2-negative patients
Si, Pilei
Chen, Tao
Fang, Bin
Yao, Jiabing
Liu, Gaoxiu
Chen, Haijun
Zhai, Baoping
Li, Wentao
CANCER MEDICINE, 2017, 6 (12): : 2832 - 2839
[37] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Wang, Wei
Zhu, Tingting
Chen, Hao
Yao, Yongzhong
CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (06) : 1673 - 1681
[38] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
Luciana de Moura Leite
Marcelle Goldner Cesca
Monique Celeste Tavares
Debora Maciel Santana
Erick Figueiredo Saldanha
Paula Tavares Guimarães
Daniella Dias Silva Sá
Maria Fernanda Evangelista Simões
Rafael Lima Viana
Francisca Giselle Rocha
Simone Klog Loose
Sinara Figueiredo Silva
Rafaela Pirolli
Camilla Albina Zanco Fogassa
Bruna Raphaeli Silva Mattos
Fernando Augusto Batista Campos
Solange Moraes Sanches
Vladmir Cláudio Cordeiro de Lima
Noam Falbel Pondé
Breast Cancer Research and Treatment, 2021, 190 : 155 - 163
[39] Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells
Kurbacher, C. M.
Quade, A.
Eichler, C.
Kunstmann, G.
Herz, S.
Kurbacher, J. A.
Warm, M. R.
CANCER RESEARCH, 2016, 76
[40] HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Nadine S. van den Ende
Marcel Smid
Annemieke Timmermans
Johannes B. van Brakel
Tim Hansum
Renée Foekens
Anita M. A. C. Trapman
Bernadette A. M. Heemskerk-Gerritsen
Agnes Jager
John W. M. Martens
Carolien H. M. van Deurzen
Scientific Reports, 12

← 1 2 3 4 5 →